The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: A 1-year follow-up study

European Respiratory Journal

Volumn 28, Issue 1, 2006, Pages 138-143

  Hughes, Rodney J ^a   Jais, X ^b   Bonderman, D ^c   Suntharalingam, J ^a   Humbert, M ^b   Lang, I ^c   Simonneau, G ^b   Pepke Zaba, J ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bosentan; Chronic thromboembolic pulmonary hypertension; Endothelin; Pulmonary hypertension; Thromboembolic

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; OXYGEN; PROSTACYCLIN; UNIPROST; WARFARIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDARTERECTOMY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART CATHETERIZATION; HEART INDEX; HEART TAMPONADE; HUMAN; LIVER DYSFUNCTION; LUNG FUNCTION; LUNG HEMODYNAMICS; LUNG RESISTANCE; MALE; MONOTHERAPY; OUTCOMES RESEARCH; PATIENT MONITORING; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; WALKING;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONAMIDES; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748750716     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00135905     Document Type: Article

References (29)

1. Fedullo PF, Auger WR, Channick RN, Moser KM, Jamieson SW. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 1995; 16: 353-374.
2. Houk VN, Hufnagel CA, McClenathan JE, Moser KM. Chronic thrombotic obstruction of major pulmonary arteries. Report of a case successfully treated by thrombendarterectomy, and a review of the literature. Am J Med 1963; 35: 269-282.
3. Moser KM, Auger WR, Fedullo PF, Jamieson SW. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Respir J 1992; 5: 334-342.
4. Jamieson SW. Pulmonary thromboendarterectomy. Heart 1998; 79: 118-120.
5. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76: 1457-1462.
6. Madani MM, Jamieson SW. Chronic thromboembolic pulmonary hypertension. Curr Treat Options Cardiovasc Med 2000; 2: 141-148.
7. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
8. Thistlethwaite PA, Mo M, Madani MM, et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 2002; 124: 1203-1211.
9. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685-692.
10. Bresser P, Fedullo PF, Auger WR, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23: 595-600.
11. Scelsi L, Ghio S, Campana C, et al. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. Ital Heart J 2004; 5: 618-623.
12. Nagaya N, Shimizu Y, Satoh T, et al. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 2002; 87: 340-345.
13. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151-155.
14. Ono F, Nagaya N, Okumura H, et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003; 123: 1583-1588.
15. Roig Figueroa V, Herrero Perez A, de la Torre Ferrera N, et al. Iloprost for chronic thromboembolic pulmonary hypertension. Arch Bronconeumol 2004; 40: 326-328.
16. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139-1141.
17. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
18. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034-1036.
19. Battistini B, Verreault M, Ayach B, et al. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model. J Cardiovasc Pharmacol 2004; 44: S386-S389.
20. Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000; 15: 640-648.
21. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
22. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-254.
23. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on i.v. epoprostenol. Thorax 2005; 60: 1025-1030.
24. Hughes R, George P, Parameshwar J, et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 2005; 60: 707.
25. Hoeper MM, Kramm T, Wilkens H, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005; 128: 2363-2367.
26. Bonderman D, Nowotny R, Skoro-Sajer N, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005; 128: 2599-2603.
27. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16: 13-18.
28. Zoia MC, D'Armini AM, Beccaria M, et al. Mid term effects of pulmonary thromboendarterectomy on clinical and cardiopulmonary function status. Thorax 2002; 57: 608-612.
29. Riedel M, Stanek V, Widimsky J, Prerovsky I. Long-term follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982; 81: 151-158.